• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
TONG Xinyong, LI Limin. Preparation of levobupivacaine hydrochloride sustained-release in-situ gel injection and its pharmacokinetic and pharmacodynamic studies in animals[J]. Journal of China Pharmaceutical University, 2015, 46(2): 209-213. DOI: 10.11665/j.issn.1000-5048.20150212
Citation: TONG Xinyong, LI Limin. Preparation of levobupivacaine hydrochloride sustained-release in-situ gel injection and its pharmacokinetic and pharmacodynamic studies in animals[J]. Journal of China Pharmaceutical University, 2015, 46(2): 209-213. DOI: 10.11665/j.issn.1000-5048.20150212

Preparation of levobupivacaine hydrochloride sustained-release in-situ gel injection and its pharmacokinetic and pharmacodynamic studies in animals

More Information
  • The purpose of this study was to develop a novel phospholipidas-based in-situ gel sustained-release formulation of levobupivacaine hydrochloride injection. Appropriate formulation was screened based on the factors such as phospholipid type, ratio of phospholipid to ethanol, ratio of water to phospholipid-ethanol mixture, which indicated typical in-situ gel profiles. Pharmacokinetic study using beagles showed that there were delayed tmax and prolonged t1/2 in levobupivacaine plasma-time profile after administration of the phospholipidas-based in-situ gel formulation if compared to commercially available conventional levobupivacaine hydrochloride injection. Pharmacodynamic studies conducted on guinea-pig demonstrated that it maintained 48-72 hr regional anesthesia, much longer than that of the anesthesia in the group receiving conventional injection. Hence, this novel in-situ gel intended for injection is worthy of development.
  • [1]
    Andrea C, Marta P. Bupivacaine, levobupivacaine and ropivacaine:are they clinically different[J]?Best Pract Res Clin Anaesthesiol,2005,19(2):247-268.
    [2]
    Bajwa SJ,Kaur J.Clinical profile of levobupivacaine in regional anesthesia:a systematic review[J].J Anaesthesiol Clin Pharmacol,2013,29(4):530-539.
    [3]
    Tong YC,Kaye AD,Urman RD.Liposomal bupivacaine and clinical outcomes[J].Best Pract Res Clin Anaesthesiol,2014,28(1):15-27.
    [4]
    McAlvin JB,Reznor G,Shankarappa SA,et al.Local toxicity from local anesthetic polymeric microparticles[J].Anesth Analg,2013,116(4):794-803.
    [5]
    Zeng HL,Shi Z,Fu XD.Progress in clinical application of the bupivacaine liposome injectable suspension Exparel[J].ChinJ New Drugs(中国新药杂志),2014,23(14):1654-1658.
    [6]
    Judy S,Michael R.Sustained-Release Injectable Products(可注射缓释制剂)[M].Beijing:Chemical Industry Press,2005:136-137,152.
    [7]
    Skolnik A,Gan TJ.New formulations of bupivacaine for the treatment of postoperative pain:liposomal bupivacaine and SABER-Bupivacaine[J].Expert Opin Pharmacother,2014,15(11):1535-1542.
    [8]
    Qi N, Tang X, Lin X, et al. Sterilization stability of vesicular phospholipid gels loaded with cytarabine for brain implant[J].Int J Pharm,2012,427(2):234-241.
    [9]
    Zhang RZ, Deng YJ, Sun WP. Research progressin vesicular phospholipid gel[J].Chin J Pharm(中国药剂学杂志),2008,6(4):214-218.

Catalog

    Article views (1400) PDF downloads (2943) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return